Imprinted antibody responses against SARS-CoV-2 Omicron sublineages.
Journal
bioRxiv : the preprint server for biology
Titre abrégé: bioRxiv
Pays: United States
ID NLM: 101680187
Informations de publication
Date de publication:
22 Aug 2022
22 Aug 2022
Historique:
pubmed:
10
6
2022
medline:
10
6
2022
entrez:
9
6
2022
Statut:
epublish
Résumé
SARS-CoV-2 Omicron sublineages carry distinct spike mutations and represent an antigenic shift resulting in escape from antibodies induced by previous infection or vaccination. We show that hybrid immunity or vaccine boosters result in potent plasma neutralizing activity against Omicron BA.1 and BA.2 and that breakthrough infections, but not vaccination-only, induce neutralizing activity in the nasal mucosa. Consistent with immunological imprinting, most antibodies derived from memory B cells or plasma cells of Omicron breakthrough cases cross-react with the Wuhan-Hu-1, BA.1 and BA.2 receptor-binding domains whereas Omicron primary infections elicit B cells of narrow specificity. While most clinical antibodies have reduced neutralization of Omicron, we identified an ultrapotent pan-variant antibody, that is unaffected by any Omicron lineage spike mutations and is a strong candidate for clinical development.
Identifiants
pubmed: 35677069
doi: 10.1101/2022.05.08.491108
pmc: PMC9176643
pii:
doi:
Types de publication
Preprint
Langues
eng
Subventions
Organisme : NIAID NIH HHS
ID : DP1 AI158186
Pays : United States
Organisme : NIAID NIH HHS
ID : HHSN272201700059C
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI163019
Pays : United States
Commentaires et corrections
Type : UpdateIn
Déclaration de conflit d'intérêts
Competing interests: D.P., Ad.M., F.Z., M.G., C.S.F., J.B., C.S., H.V.D., K.H., W.R., M.A.S., G.Sc., B.G., F.B., J.d.I., A.R., J.Z., N.F., H.K., M.M.R, J.N., F.A.L., G.S., L.P., H.W.V., A.L., M.S.P. and D.C. are employees of Vir Biotechnology Inc. and may hold shares in Vir Biotechnology Inc. L.A.P. is a former employee and shareholder in Regeneron Pharmaceuticals. Regeneron provided no funding for this work. H.W.V. is a founder and holds shares in PierianDx and Casma Therapeutics. Neither company provided resources. D.C. is currently listed as an inventor on multiple patent applications, which disclose the subject matter described in this manuscript. The Veesler laboratory has received a sponsored research agreement from Vir Biotechnology Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Nat Med. 2022 May;28(5):1063-1071
pubmed: 35189624
Science. 2021 Dec 24;374(6575):1621-1626
pubmed: 34751595
Cell. 2022 Mar 3;185(5):872-880.e3
pubmed: 35123650
Nat Commun. 2022 Jul 2;13(1):3824
pubmed: 35780162
Nature. 2021 Oct;598(7880):342-347
pubmed: 34464958
Science. 2022 Aug 12;377(6607):735-742
pubmed: 35857703
Science. 2021 Aug 27;373(6558):991-998
pubmed: 34214046
Nat Med. 2022 Jun;28(6):1297-1302
pubmed: 35322239
Science. 2022 Aug 5;377(6606):eabq0839
pubmed: 35857620
Science. 2022 Jan 28;375(6579):449-454
pubmed: 34990214
Nature. 2021 Feb;590(7845):320-325
pubmed: 33260195
JAMA. 2022 Feb 15;327(7):639-651
pubmed: 35060999
Cell. 2022 Feb 3;185(3):447-456.e11
pubmed: 35026151
Structure. 2019 Jan 2;27(1):134-139.e3
pubmed: 30344107
Science. 2022 Jul 22;377(6604):420-424
pubmed: 35762884
Nature. 2020 Jul;583(7815):290-295
pubmed: 32422645
J Mol Graph. 1996 Feb;14(1):33-8, 27-8
pubmed: 8744570
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
Nature. 2022 Feb;602(7898):664-670
pubmed: 35016195
J Comput Chem. 2004 Oct;25(13):1605-12
pubmed: 15264254
Science. 2022 Nov 25;378(6622):eabo2523
pubmed: 36302057
Nat Methods. 2017 Mar;14(3):290-296
pubmed: 28165473
Elife. 2016 Sep 26;5:
pubmed: 27669148
Science. 2021 Feb 12;371(6530):735-741
pubmed: 33436524
Cell Rep. 2022 May 17;39(7):110812
pubmed: 35568025
Nat Commun. 2022 Oct 23;13(1):6309
pubmed: 36274085
Nature. 2022 Mar;603(7902):679-686
pubmed: 35042229
J Exp Med. 2011 Jan 17;208(1):181-93
pubmed: 21220454
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
J Chem Theory Comput. 2015 Aug 11;11(8):3696-713
pubmed: 26574453
Nature. 2022 Feb;602(7898):671-675
pubmed: 35016199
Sci Transl Med. 2022 Aug 17;14(658):eabq4130
pubmed: 35976993
J Phys Chem B. 2008 Jul 31;112(30):9020-41
pubmed: 18593145
Science. 2021 Feb 19;371(6531):823-829
pubmed: 33495307
IUCrJ. 2019 Jan 01;6(Pt 1):5-17
pubmed: 30713699
Nature. 2021 Sep;597(7874):97-102
pubmed: 34261126
Front Immunol. 2022 Jul 19;13:946318
pubmed: 35928813
Cell Rep. 2020 Sep 1;32(9):108088
pubmed: 32877670
Nature. 2021 Sep;597(7874):103-108
pubmed: 34280951
J Mol Biol. 2003 Oct 31;333(4):721-45
pubmed: 14568533
Nat Biotechnol. 2020 Sep;38(9):1073-1078
pubmed: 32704169
Sci Immunol. 2022 Sep 16;7(75):eabq2427
pubmed: 35653438
N Engl J Med. 2022 Mar 17;386(11):1088-1091
pubmed: 35081298
JAMA. 2022 Jan 11;327(2):179-181
pubmed: 34914825
Sci Transl Med. 2022 Apr 20;14(641):eabn6150
pubmed: 35258323
Cell Host Microbe. 2020 Sep 9;28(3):475-485.e5
pubmed: 32735849
Science. 2021 Sep 03;373(6559):1109-1116
pubmed: 34344823
Nat Med. 2022 Nov;28(11):2388-2397
pubmed: 36202997
J Comput Chem. 2018 Sep 30;39(25):2110-2117
pubmed: 30368859
Science. 2011 Aug 12;333(6044):850-6
pubmed: 21798894
Ultramicroscopy. 2013 Dec;135:24-35
pubmed: 23872039
Acta Crystallogr D Biol Crystallogr. 2010 Apr;66(Pt 4):486-501
pubmed: 20383002
Cell. 2021 Mar 4;184(5):1171-1187.e20
pubmed: 33621484
Science. 2020 Nov 20;370(6519):950-957
pubmed: 32972994
Cell. 2022 Apr 28;185(9):1556-1571.e18
pubmed: 35447072
Nature. 2021 Mar;591(7851):639-644
pubmed: 33461210
N Engl J Med. 2022 Apr 21;386(16):1579-1580
pubmed: 35294809
Sci Transl Med. 2021 Jun 30;13(600):
pubmed: 34103407
Cell Host Microbe. 2022 Sep 14;30(9):1231-1241.e6
pubmed: 35921836
J Exp Med. 2021 Mar 1;218(3):
pubmed: 33211088
Cell. 2022 Feb 3;185(3):457-466.e4
pubmed: 34995482
Sci Immunol. 2022 Dec 23;7(78):eadf1421
pubmed: 36356052
Nature. 2022 Mar;603(7902):700-705
pubmed: 35104835
N Engl J Med. 2021 Oct 7;385(15):1401-1406
pubmed: 34407341
EBioMedicine. 2022 Jan;75:103788
pubmed: 34954658
Elife. 2018 Nov 09;7:
pubmed: 30412051
Nat Commun. 2020 Nov 17;11(1):5838
pubmed: 33203860
Acta Crystallogr D Struct Biol. 2018 Jun 1;74(Pt 6):519-530
pubmed: 29872003
Eur J Immunol. 2009 May;39(5):1260-70
pubmed: 19404981
Science. 2021 Dec 10;374(6573):1343-1353
pubmed: 34672695
J Med Virol. 2022 May;94(5):1808-1810
pubmed: 35043399
Cell Host Microbe. 2022 Jun 8;30(6):880-886.e4
pubmed: 35436444
Nat Methods. 2020 Dec;17(12):1214-1221
pubmed: 33257830
Sci Transl Med. 2022 Aug 17;14(658):eabn6868
pubmed: 35511920
J Struct Biol. 2005 Jul;151(1):41-60
pubmed: 15890530
Sci Immunol. 2021 Dec 10;6(66):eabj5129
pubmed: 34890255
Science. 2016 Nov 11;354(6313):722-726
pubmed: 27846599
Cell. 2021 Oct 14;184(21):5432-5447.e16
pubmed: 34619077
Nat Microbiol. 2021 Oct;6(10):1233-1244
pubmed: 34548634
Nature. 2022 Feb;602(7898):676-681
pubmed: 35016198
Nat Chem. 2021 Oct;13(10):963-968
pubmed: 34413500
Cell. 2020 Nov 12;183(4):1024-1042.e21
pubmed: 32991844
Nat Methods. 2019 Nov;16(11):1146-1152
pubmed: 31591575
Science. 2022 Feb 25;375(6583):864-868
pubmed: 35076256
Science. 2021 Mar 25;:
pubmed: 33766944
Nature. 2021 Nov;599(7883):114-119
pubmed: 34488225
Nature. 2021 Jul;595(7867):426-431
pubmed: 34126625
Cell Rep Med. 2021 Apr 20;2(4):100230
pubmed: 33754147
Science. 2020 Oct 30;370(6516):571-575
pubmed: 32913002
Nature. 2020 May;581(7807):215-220
pubmed: 32225176
Lancet Microbe. 2022 Dec;3(12):e898
pubmed: 35963276
Cell. 2019 Feb 21;176(5):1026-1039.e15
pubmed: 30712865
J Comput Chem. 2008 Mar;29(4):622-55
pubmed: 17849372
Cell. 2021 Apr 29;184(9):2332-2347.e16
pubmed: 33761326
N Engl J Med. 2022 May 5;386(18):1764-1766
pubmed: 35320661